BA
PFE icon

Bivin & Associates’s Pfizer PFE Stock Holding History

Bivin & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$35K Hold
672
– – 0.04% 87
2022
Q1 		$35K Buy
672
+53
+9% +$2.75K 0.03% 99
2021
Q4 		$37K Buy
+619
New +$30.7K 0.03% 102

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bivin & Associates's PFE Position: Q2 2022 in Review

Bivin & Associates held its Pfizer (PFE) position steady in Q2 2022 at 672 shares worth $35K. The position accounts for 0.04% of the portfolio, ranked #87.

Bivin & Associates first reported a position in PFE in Q4 2021 and has held it in 3 quarters since. The position peaked at $37K in Q4 2021. 3,158 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

  • Bivin & Associates held 672 shares of Pfizer worth $35K as of Q2 2022.
  • Bivin & Associates left its Pfizer share count unchanged in Q2 2022.
  • Pfizer made up 0.04% of Bivin & Associates's portfolio in Q2 2022, its #87 holding.
  • Bivin & Associates first reported a position in Pfizer in Q4 2021 and has held it in 3 quarters since.
  • Bivin & Associates's Pfizer position peaked at $37K in Q4 2021.
  • 3,158 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.